Journal
FRONTIERS IN MICROBIOLOGY
Volume 12, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fmicb.2021.791274
Keywords
microbiota; esophageal adenocarcinoma; Barrett's esophagus; gastroesophageal reflux disease; microbial therapy
Categories
Funding
- Science Technological Innovation Nursery Fund of Chinese PLA General Hospital [18KMM02]
- Young Scholar Medical Research Fund of Chinese PLA General Hospital [QNC19044]
- Medical Science and Technology Young Scholar Fostering Fund [21QNPY109]
Ask authors/readers for more resources
Esophageal adenocarcinoma (EAC) is a subtype of esophageal cancer that has been found to be affected by the human microbiota. Research has shown that specific bacterial alternations in the human microbiota play a role in the development of EAC through inflammation, microbial metabolism, and genotoxicity. This emerging field of study provides potential microbiome-based clinical applications for the prevention, diagnosis, prognosis, and therapy of EAC.
Esophageal adenocarcinoma (EAC) is one of the main subtypes of esophageal cancer. The incidence rate of EAC increased progressively while the 5-year relative survival rates were poor in the past two decades. The mechanism of EAC has been studied extensively in relation to genetic factors, but less so with respect to human microbiota. Currently, researches about the relationship between EAC and the human microbiota is a newly emerging field of study. Herein, we present the current state of knowledge linking human microbiota to esophageal adenocarcinoma and its precursor lesion-gastroesophageal reflux disease and Barrett's esophagus. There are specific human bacterial alternations in the process of esophageal carcinogenesis. And bacterial dysbiosis plays an important role in the process of esophageal carcinogenesis via inflammation, microbial metabolism and genotoxicity. Based on the human microbiota alternation in the EAC cascade, it provides potential microbiome-based clinical application. This review is focused on novel targets in prevention, diagnosis, prognosis, and therapy for esophageal adenocarcinoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available